中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
Engineered tumor-symbiotic bacterial membrane nanovesicles enable precise immuno-chemotherapy of colorectal cancer

文献类型：期刊论文

作者Lu, Shengwei3,4,5; Miao, Yunqiu4,5; Wang, Dandan4,5; Xu, Dan4,5; Liu, Ruichi4,5; Liu, Xinrui4,5; Zhang, Yang2,4; Zhang, Xinxin1,6; Qin, Huanlong4,5
刊名JOURNAL OF CONTROLLED RELEASE
出版日期2025-12-10
卷号388页码:14
关键词Bacteria-derived therapy Fusobacterium nucleatum Bacterial membrane vesicles Colorectal cancer Immunochemotherapy
ISSN号0168-3659
DOI10.1016/j.jconrel.2025.114291
通讯作者Miao, Yunqiu(yunqiumiao@tongji.edu.cn) ; Zhang, Yang(zhangyang0202@tongji.edu.cn) ; Zhang, Xinxin(xinxinzhang@simm.ac.cn) ; Qin, Huanlong(hlongqin@126.com)
英文摘要Gut microorganisms show promising therapeutic effects and drug delivery potential for colorectal cancer (CRC) treatment, but are limited by their insufficient targeting ability and side effects. Fusobacterium nucleatum (Fn) is a key symbiotic bacterium in CRC, which can preferentially accumulate in tumor tissues and invade tumor cells, while its tumorigenicity restricts the application in drug delivery. Herein, we engineered Fn with anchored PD-L1 antibody (alpha PD-L1), and then isolated the Fn membranes to construct bacterial membrane nanovesicles (abFMNVs) for precise delivery of chemotherapeutic drugs. The ab-FMNVs exploited Fn's inherent tumor colonization capabilities to achieve tumor-targeted delivery through the specific membrane protein FadA-mediated pathway, and modulated the PD-L1 immune checkpoint pathway for tumor immunotherapy. Simultaneously, ab-FMNVs were internalized into CT26 cells to release the chemotherapeutic agent doxorubicin, synergistically inhibiting tumor cell proliferation and metastasis. In a CRC-bearing mouse model, doxorubicin-loaded ab-FMNVs increased tumor accumulation and demonstrated superior antitumor efficacy against both primary and recurrent CRC progression without inducing any side effects. This innovative approach holds promise for precision cancer therapies by harnessing the symbiotic relationship between bacteria and CRC.
WOS关键词FUSOBACTERIUM-NUCLEATUM
资助项目National Key Research and Development Program of China[2022YFC2304104] ; National Natural Science Foundation of China[82104113] ; National Natural Science Foundation of China[82222066] ; Natural Science Foundation of Shanghai[25ZR1402427]
WOS研究方向Chemistry ; Pharmacology & Pharmacy
语种英语
WOS记录号WOS:001594079100003
出版者ELSEVIER
源URL[http://119.78.100.183/handle/2S10ELR8/321681]  
专题中国科学院上海药物研究所
通讯作者Miao, Yunqiu; Zhang, Yang; Zhang, Xinxin; Qin, Huanlong
作者单位1.Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, Yantai 264117, Shandong, Peoples R China
2.Shanghai Eighth Peoples Hosp, Dept Pharm, Shanghai 200235, Peoples R China
3.Huzhou Univ, Affiliated Hosp 1, Peoples Hosp Huzhou 1, Emergency Intens Care Unit, Huzhou City 313000, Zhejiang, Peoples R China
4.Tongji Univ, Shanghai Peoples Hosp 10, Nanomed & Intestinal Microecol Res Ctr, Sch Med, Shanghai 200072, Peoples R China
5.Tongji Univ, Gen Surg Shanghai Peoples Hosp 10, Sch Med, Dept Funct Intestinal Dis, Shanghai 200072, Peoples R China
6.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 Lu, Shengwei,Miao, Yunqiu,Wang, Dandan,et al. Engineered tumor-symbiotic bacterial membrane nanovesicles enable precise immuno-chemotherapy of colorectal cancer[J]. JOURNAL OF CONTROLLED RELEASE,2025,388:14.
APA Lu, Shengwei.,Miao, Yunqiu.,Wang, Dandan.,Xu, Dan.,Liu, Ruichi.,...&Qin, Huanlong.(2025).Engineered tumor-symbiotic bacterial membrane nanovesicles enable precise immuno-chemotherapy of colorectal cancer.JOURNAL OF CONTROLLED RELEASE,388,14.
MLA Lu, Shengwei,et al."Engineered tumor-symbiotic bacterial membrane nanovesicles enable precise immuno-chemotherapy of colorectal cancer".JOURNAL OF CONTROLLED RELEASE 388(2025):14.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。